Bleeding risk during oral anticoagulation therapy for atrial fibrillation

The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation

(2013) Daniel E. Singer   ANNALS OF INTERNAL MEDICINE

Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies

(2013) Neil S. Roskell et al.   EUROPACE

Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation

(2012) Deirdre A. Lane et al.   CIRCULATION

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPACE

Oral anticoagulation use by patients with atrial fibrillation in Germany

(2012) Antje Groth et al.   THROMBOSIS AND HAEMOSTASIS

Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis

(2011) G. Y. H. Lip et al.   EUROPACE

Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions

(2011) Andrea Gerth et al.   THROMBOSIS AND HAEMOSTASIS

Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study

(2011) Gregory Lip et al.   THROMBOSIS AND HAEMOSTASIS

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study

(2011) Amitava Banerjee et al.   THROMBOSIS AND HAEMOSTASIS

Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation

(2009) Carl van Walraven et al.   STROKE